drugset
drugset / Trial / NCT03805581

Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

NCT03805581 ↗

Phase 2 Completed 20 enrolled New York Medical College Johns Hopkins University · collab
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).

Timeline

Start
2018-01-12
Primary completion
2022-07-01
Completion
2023-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Defibrotide Oligonucleotide (other) 6.25 mg/kg Intravenous

Indications

acute chest syndrome sickle cell disease